Form 4: Centessa Pharmaceuticals Director Goyal Arjun Acquires Additional Shares

Director Goyal Arjun reports purchasing additional Centessa Pharmaceuticals shares through multiple transactions.

Summary

• On May 15, 2025, Goyal Arjun, a director of Centessa Pharmaceuticals plc, acquired 44,939 ordinary shares at a weighted average price of $12.2441, with individual prices ranging from $11.99 to $12.50.
• On May 16, 2025, Goyal Arjun acquired 417,646 ordinary shares at a weighted average price of $12.7261, with individual prices ranging from $12.45 to $13.00.
• Following these transactions, Goyal Arjun beneficially owns 462,585 shares through Vinyanshu Ventures LLC, an entity he controls.
• Goyal Arjun disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's purchase suggests confidence, but it's a routine transaction disclosure.

Positives

• The director's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Director share purchases are common and closely watched as indicators of management's sentiment about the company's prospects. It is a legal requirement for company directors to report their transactions.

Stakeholder Impact

• The share purchase could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Centessa Pharmaceuticals, CNTA, Goyal Arjun, share acquisition, Form 4, director, Vinyanshu Ventures LLC, beneficial ownership